常见体外药物相互作用研究缺陷有哪些？
Certara drug interaction science experts share data and experimental design gaps commonly found in in…
Certara2025 年 6 月 9 日
Clinical and Physiologically Based Pharmacokinetic Model Evaluations of Adagrasib Drug–Drug Interactions
Director, Clinical Pharmacology, ORIC Pharmaceuticals SVP, Head of Simcyp PBPK Modeling Services, Certara Director, PBPK…
Certara2025 年 4 月 21 日
Measuring metabolites in index clinical DDI studies
2025 年 2 月 7 日A key drug development safety consideration is whether the drug candidate will interact…
Certara2025 年 2 月 7 日
Optimizing DDI Knowledge throughout Drug Development
Lorem ipsum dolor sit amet consectetur. Donec diam risus volutpat tempor. Massa accumsan aliquam nibh…
Certara2025 年 1 月 6 日
Static Versus Dynamic Model Predictions of Competitive Inhibitory Metabolic Drug–Drug Interactions via Cytochromes P450: One Step Forward and Two Steps Backwards
Predicting metabolic drug–drug interactions (DDIs) via cytochrome P450 enzymes (CYP) is essential in drug development,…
Certara2024 年 12 月 12 日
Prediction of CYP-mediated DDIs involving inhibition: Approaches to address the requirements for system qualification of the Simcyp Simulator
The article "Prediction of CYP-mediated DDIs involving inhibition: Approaches to address the requirements for system…
Certara2024 年 8 月 26 日
